Lumos Diagnostics (ASX:LDX) share price up 9% on evaluation update

Another gust of wind behind Lumos Diagnostics' shares today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Lumos Diagnostics Holdings Ltd (ASX: LDX) share price is jumping 9% into the green today, tipping 95 cents a share before settling back to around 91 cents apiece.

Lumos shares are on the move after the company announced positive readouts from a study concerning its FebriDx diagnostic test.

Here's what we know.

What did Lumos Diagnostics announce today?

The Australian producer of point-of-care diagnostic technologies revealed that its FebriDx diagnostic test was advocated in a prestigious health journal.

The FebriDx is a revolutionary blood test that helps distinguish between viral and bacterial sources of infection. This ultimately helps improve decision making when prescribing antibiotics.

The Journal of Health Economics and Outcomes Research (JHEOR) published a study that concluded using FebriDx "to guide antibiotic treatment for patients presenting with acute respiratory infections (ARIs)" could potentially lead to an annual saving of up to $2.5 billion for the US healthcare system.

Considering the US spent more than US$11,500 per person on healthcare in 2019, according to the US Centre for Medicare and Medicaid Services (CMS), this comes in at a saving of $7.60 per person, or 0.07%.

The authors of the article, Avalon Health Economics, compared 2 scenarios that looked at antibiotic prescription and adverse reactions.

One scenario involved the inclusion of FebriDx compared to a "control" scenario without FebriDx's diagnostic tool.

This is what led researchers to believe an annual $2.5 billion in costs savings could be achieved.

Curiously, estimates suggest "around half of the antibiotics prescribed for ARI's in outpatient settings are medically unnecessary", according to the company's announcement.

Plus, costs associated with these reactions are estimated to be between US$1,156/visit and US$14,678/event for ED visits and hospitalisations respectively.

Lumos intends to make a dent in these numbers with its FebriDx test and, now with additional literature supporting its case, it is one step closer to making it happen.

Lumos Diagnostics share price snapshot

The Lumos Diagnostics share price is swimming in a sea of red and has been since listing back in July. It's given shareholders a loss of 24% since this time, extending its slide in the past week 1.5%

These results have lagged the benchmark S&P/ASX 200 Index (ASX: XJO) over this time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured a rough day of trading this Tuesday.

Read more »

A mature-aged couple high-five each other as they celebrate a financial win and early retirement
Share Gainers

Why this ASX 300 stock is soaring 12% after a disastrous year

This company has had a dramatic reversal of fortunes this Tuesday...

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher

These shares are having a good session. What's going on?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

4 ASX All Ords shares up 315% to 682% in a year!

Investors have sent these ASX All Ords shares flying higher. But why?

Read more »

Man standing on rock next to turquoise salt lagoon.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors enjoyed a great start to the trading week today.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Share Gainers

Why Austal, Breville, Telix, and Westgold shares are pushing higher today

These shares are starting the week positively. But why?

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a rough Friday to close the trading week today.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Pointsbet, Qantas, Serko, and Yandal shares are pushing higher today

These shares are avoiding the market selloff today. But why?

Read more »